Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$45.77 -0.3%	$39.79	$21.72 ▼ $48.68	$8.72B	1.15	2.56 million shs	2.11 million shs
BPMC Blueprint Medicines	$129.46	$120.01	$73.04 ▼ $129.65	$8.36B	0.89	1.54 million shs	N/A
NAMS NewAmsterdam Pharma	$22.93 +1.6%	$19.35	$14.06 ▼ $27.29	$2.53B	-0.03	751,579 shs	1.19 million shs
ROIV Roivant Sciences	$11.50 +0.2%	$11.17	$8.73 ▼ $13.06	$7.80B	1.15	5.75 million shs	3.83 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-1.31%	-3.75%	+9.99%	+34.29%	+75.26%
BPMC Blueprint Medicines	0.00%	+0.08%	+0.98%	+55.21%	+12.60%
NAMS NewAmsterdam Pharma	+1.62%	+1.76%	+25.61%	+34.37%	+19.37%
ROIV Roivant Sciences	+0.35%	-1.29%	+0.26%	+10.17%	+4.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6072 of 5 stars	4.5	1.0	3.9	2.9	3.3	0.6
BPMC Blueprint Medicines	1.0983 of 5 stars	2.1	2.0	0.0	2.1	0.8	0.6
NAMS NewAmsterdam Pharma	3.6107 of 5 stars	4.4	2.0	0.0	1.9	5.0	0.0
ROIV Roivant Sciences	2.8124 of 5 stars	3.6	3.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$61.50	34.37% Upside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.93% Downside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.30	80.11% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	43.48% Upside

Current Analyst Ratings Breakdown

Latest NAMS, BPMC, BBIO, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$66.00
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	68.21	N/A	N/A	($7.71) per share	-5.94
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
NAMS NewAmsterdam Pharma	$45.56M	56.50	N/A	N/A	$8.20 per share	2.80
ROIV Roivant Sciences	$29.05M	269.12	N/A	N/A	$7.45 per share	1.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest NAMS, BPMC, BBIO, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	N/A	N/A	N/A	$1.44 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
NAMS NewAmsterdam Pharma	89.89%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
NAMS NewAmsterdam Pharma	20.84%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

NAMS, BPMC, BBIO, and ROIV Headlines

Recent News About These Companies

Mutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

July 20 at 3:51 AM | marketbeat.com

CenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 16, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 15, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Rating Upgraded by The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?

July 9, 2025 | marketbeat.com

DAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 9, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

July 9, 2025 | marketbeat.com

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28, 2025 | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Investors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

June 26, 2025 | marketbeat.com

Penn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 25, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

June 24, 2025 | marketbeat.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23, 2025 | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, BPMC, BBIO, and ROIV Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$45.77 -0.13 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$45.96 +0.19 (+0.42%)

As of 07:50 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$129.46 0.00 (0.00%)

As of 07/18/2025

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$22.93 +0.37 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$22.75 -0.18 (-0.78%)

As of 06:58 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Roivant Sciences NASDAQ:ROIV

$11.50 +0.02 (+0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$11.48 -0.02 (-0.17%)

As of 06:06 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time